Medical Biochemistry: Comprehensive Study Guide on Proteins and Lipids

Foundations and Biological Functions of Proteins

• Fundamental Definition and Abundance:

  • Proteins represent polymers composed of L-$\alpha$-amino acid monomers linked via covalent peptide bonds.

  • They constitute the most abundant organic macromolecules in living organisms and exhibit extensive functional and structural diversity.

  • The specific, genetically encoded linear sequence of amino acids directs the three-dimensional folding conformation, which dictates the biological role of the mature protein.

• Functional Classification of Proteins:

  • Structural Proteins: Offer mechanical stability, structural framework, and tensile strength to biological tissues.

  • Collagen: Present extensively in fibrous connective tissues, tendons, bone matrix, and cartilage.

  • Keratin: Principal component of hair, epidermis, wool, and nails.

  • Contractile Proteins: Mediate mechanical movement and force generation at the cellular and tissue levels.

  • Myosin and Actin: Function in sliding-filament cross-bridge cycling to contract skeletal and cardiac muscle fibers.

  • Transport Proteins: Shuttle essential organic molecules, ions, and lipids through biological fluids and across cellular membranes.

  • Hemoglobin: Tetrameric metalloprotein that binds and delivers molecular oxygen ($\text{O}_2$) from the pulmonary capillaries to peripheral tissues.

  • Plasma Lipoproteins: Solubilize and transport hydrophobic lipids, cholesterol, and triglycerides throughout the vascular system.

  • Plasma Albumin: Maintains oncotic pressure and serves as an unspecific carrier for non-esterified free fatty acids and hydrophobic drugs.

  • Storage Proteins: Sequester essential nutritional metabolites and metal ions for physiological conservation.

  • Casein: Primary nutritional protein reservoir found in mammalian milk.

  • Ferritin: Intracellular storage complex that sequesters iron atoms primarily in the spleen, liver, and bone marrow.

  • Hormonal Proteins: Regulate endocrine signaling, metabolic rate, glucose homeostasis, and systemic physiological development.

  • Insulin: Peptide hormone secreted by pancreatic beta cells to clear glucose from blood into adipose and skeletal muscle tissue.

  • Growth Hormone: Pituitary protein regulating somatic cellular proliferation and tissue growth.

  • Enzymatic Proteins: Biocatalysts that lower activation energies to accelerate chemical reactions within cellular compartments.

  • Sucrase: Hydrolase that cleaves dietary sucrose into glucose and fructose.

  • Trypsin: Serine endopeptidase that hydrolyzes peptide linkages in the duodenum.

  • Protective / Immune Proteins: Identify, neutralize, and clear pathogenic microorganisms and foreign macromolecular antigens.

  • Immunoglobulins (Antibodies): Recognize antigenic epitopes to drive humoral immune responses.

Amino Acid Structure, Stereochemistry, and Acid-Base Properties

• General Chemical Architecture of Amino Acids:

  • Mammalian proteins are constructed from a standard repertoire of $20$ distinct L-$\alpha$-amino acids.

  • Each amino acid features a central carbon atom designated as the $\alpha$-carbon ($\text{C}_\alpha$), to which four distinct functional chemical moieties are covalently bonded:

  • A basic amino group ($-\text{NH}_2$).

  • An acidic carboxyl group ($-\text{COOH}$).

  • A hydrogen atom ($-\text{H}$).

  • A distinctive chemical side chain or R-group ($-\text{R}$) that confers unique physical and chemical characteristics.

• Stereochemical and Optical Properties:

  • The $\alpha$-carbon is tetrahedrally bonded to four non-identical chemical groups, rendering it an asymmetric or chiral stereocenter.

  • Optical Isomerism: Chiral amino acids exist as non-superimposable mirror-image stereoisomers designated as D-enantiomers and L-enantiomers.

  • Stereochemical Rule in Biology: Ribosomal protein synthesis exclusively utilizes amino acids in the L-configuration.

  • The Exception of Glycine: In glycine, the R-group is a second hydrogen atom. Because the $\alpha$-carbon is bonded to two identical hydrogen atoms, it lacks asymmetry, possesses no chiral center, and is optically inactive.

• Amphoteric Nature and Acid-Base Behavior:

  • Amino acids are ampholytes (amphoteric compounds), possessing functional groups that act as proton donors (weak acids) or proton acceptors (weak bases) depending on ambient solution $\text{pH}$.

  • Ionization States Across pH:

  • In strongly acidic solutions ($\text{pH} < 2$), the carboxyl group is fully protonated ($-\text{COOH}$) and the amino group is protonated ($-\text{NH}_3^+$), generating a net positive charge ($+1$).

  • At physiological $\text{pH}$ ($\approx 7.4$), the carboxyl group is dissociated into a negatively charged carboxylate ion ($-\text{COO}^-$), while the amino group remains protonated as an ammonium ion ($-\text{NH}_3^+$).

  • In strongly alkaline solutions ($\text{pH} > 10$), the ammonium group dissociates its proton to form a neutral amine ($-\text{NH}_2$), yielding a net negative charge ($-1$).

  • Zwitterion and Isoelectric Point ($\text{pI}$):

  • A zwitterion (dipolar ion) is an electrically neutral chemical species that simultaneously carries an equal number of positive and negative charges.

  • The isoelectric point ($\text{pI}$) is the characteristic $\text{pH}$ at which the net electrical charge of the amino acid equals zero.

  • For monoamino-monocarboxylic acids such as Alanine, the isoelectric point is the arithmetic mean of its two ionization constants:       $\text{pI} = \frac{\text{pK}_{a1} + \text{pK}_{a2}}{2} = \frac{2.34 + 9.69}{2} = 6.01$

• Physical Properties:

  • Pure amino acids are colorless, crystalline solids.

  • They exhibit high melting points due to strong ionic electrostatic lattice interactions in the zwitterionic state.

  • They are readily soluble in polar solvents (water) and substantially less soluble in nonpolar organic solvents.

  • Tyrosine possesses poor solubility in cold water but dissolves readily in boiling water.

Classification and Nomenclature of Amino Acids

• Nomenclature and One-Letter Code Assignment Rules:

  • Rule 1: Unique Initial Letter: Assigned when an amino acid possesses a distinct initial letter:

  • Cysteine ($\text{Cys}$) = $\text{C}$

  • Histidine ($\text{His}$) = $\text{H}$

  • Isoleucine ($\text{Ile}$) = $\text{I}$

  • Methionine ($\text{Met}$) = $\text{M}$

  • Serine ($\text{Ser}$) = $\text{S}$

  • Valine ($\text{Val}$) = $\text{V}$

  • Rule 2: High Frequency Occurrence Priority: In cases of duplicate initials, the most abundant amino acids in proteins receive priority for the first letter:

  • Alanine ($\text{Ala}$) = $\text{A}$

  • Glycine ($\text{Gly}$) = $\text{G}$

  • Leucine ($\text{Leu}$) = $\text{L}$

  • Proline ($\text{Pro}$) = $\text{P}$

  • Threonine ($\text{Thr}$) = $\text{T}$

  • Rule 3: Phonetic or Structural Resemblance: Assigned based on sound associations or specific structural cues:

  • Arginine ($\text{Arg}$) = $\text{R}$ ("aRginine")

  • Asparagine ($\text{Asn}$) = $\text{N}$ (contains N; amide)

  • Aspartate ($\text{Asp}$) = $\text{D}$ ("asparDic")

  • Glutamate ($\text{Glu}$) = $\text{E}$ ("glutEmate")

  • Glutamine ($\text{Gln}$) = $\text{Q}$ ("Q-tamine")

  • Phenylalanine ($\text{Phe}$) = $\text{F}$ ("Fenylalanine")

  • Tyrosine ($\text{Tyr}$) = $\text{Y}$ ("tYrosine")

  • Tryptophan ($\text{Trp}$) = $\text{W}$ (represents the double aromatic ring structure)

  • Rule 4: Alphabetical Proximity and Indeterminate Residues:

  • Lysine ($\text{Lys}$) = $\text{K}$ (letter preceding L in the alphabet)

  • Aspartate or Asparagine ($\text{Asx}$) = $\text{B}$ (alphabetically near A)

  • Glutamate or Glutamine ($\text{Glx}$) = $\text{Z}$

  • Undetermined or unknown amino acid = $\text{X}$

• Side-Chain Structural Classification:

  • Non-Polar (Hydrophobic) Amino Acids:

  • Possess hydrocarbon or aromatic side chains that do not gain or lose protons, remaining uncharged and unable to participate in hydrogen or ionic bonding.

  • Glycine ($\text{Gly, G}$): $-\text{H}$ (smallest, $\text{pK}_1 = 2.3$, $\text{pK}_2 = 9.6$).

  • Alanine ($\text{Ala, A}$): $-\text{CH}_3$.

  • Valine ($\text{Val, V}$): $-\text{CH(CH}_3)_2$ (branched aliphatic).

  • Leucine ($\text{Leu, L}$): $-\text{CH}_2\text{CH(CH}_3)_2$ (branched aliphatic).

  • Isoleucine ($\text{Ile, I}$): $-\text{CH(CH}_3)\text{CH}_2\text{CH}_3$ (chiral side chain).

  • Phenylalanine ($\text{Phe, F}$): $-\text{CH}_2\text{-phenyl}$ (non-polar aromatic benzyl group).

  • Tryptophan ($\text{Trp, W}$): $-\text{CH}_2\text{-indole}$ ring (bicyclic aromatic structure).

  • Methionine ($\text{Met, M}$): $-\text{CH}_2\text{CH}_2\text{-S-CH}_3$ (non-polar thioether).

  • Proline ($\text{Pro, P}$): Cyclic secondary amino acid (imino acid) where the side chain loops back to covalently bond to the primary amino nitrogen, imparting rigid steric constraints.

• Uncharged Polar Amino Acids:

  • Display neutral net electrical charge at physiological $\text{pH}$, but contain polar moieties capable of participating in hydrogen bonding.

  • Serine ($\text{Ser, S}$): $-\text{CH}_2\text{OH}$ (primary aliphatic hydroxyl).

  • Threonine ($\text{Thr, T}$): $-\text{CH(OH)CH}_3$ (secondary aliphatic hydroxyl).

  • Tyrosine ($\text{Tyr, Y}$): $-\text{CH}_2\text{-phenol}$ ($\text{pK}_1 = 2.2$, $\text{pK}_2 = 9.1$, phenolic $\text{pK}_3 = 10.1$).

  • Asparagine ($\text{Asn, N}$): $-\text{CH}_2\text{CONH}_2$ (terminal amide derivative of aspartate).

  • Glutamine ($\text{Gln, Q}$): $-\text{CH}_2\text{CH}_2\text{CONH}_2$ (terminal amide derivative of glutamate).

  • Cysteine ($\text{Cys, C}$): $-\text{CH}_2\text{SH}$ ($\text{pK}_1 = 1.7$, thiol $\text{pK}_2 = 8.3$, ammonium $\text{pK}_3 = 10.8$). Two cysteine thiol ($-\text{SH}$) groups can undergo oxidation to form a covalent disulfide bridge ($-\text{S}-\text{S}-$).

• Acidic Amino Acids (Dicarboxylic Acids):

  • Act as proton donors; side-chain carboxyl groups dissociate at neutral $\text{pH}$ to carry a net negative charge ($-1$).

  • Aspartic Acid / Aspartate ($\text{Asp, D}$): $-\text{CH}_2\text{COOH}$ ($\text{pK}_1 = 2.1$, side-chain $\text{pK}_2 = 3.9$, amino $\text{pK}_3 = 9.8$).

  • Glutamic Acid / Glutamate ($\text{Glu, E}$): $-\text{CH}_2\text{CH}_2\text{COOH}$ ($\text{pK}_1 = 2.1$, side-chain $\text{pK}_2 = 4.3$, amino $\text{pK}_3 = 9.7$).

• Basic Amino Acids:

  • Act as proton acceptors; side chains contain basic nitrogenous centers that are protonated and carry positive charges at physiological $\text{pH}$.

  • Histidine ($\text{His, H}$): Contains an imidazole ring ($\text{pK}_1 = 1.8$, imidazole $\text{pK}_2 = 6.0$, amino $\text{pK}_3 = 9.2$). The near-physiological side chain $\text{pK}_a$ allows it to act as an efficient biological buffer and catalytic proton donor/acceptor.

  • Lysine ($\text{Lys, K}$): $-\text{(CH}_2)_4\text{NH}_3^+$ ($\text{pK}_1 = 2.2$, $\alpha$-amino $\text{pK}_2 = 9.2$, $\epsilon$-amino $\text{pK}_3 = 10.5$).

  • Arginine ($\text{Arg, R}$): Contains a guanidinium moiety ($\text{pK}_1 = 2.2$, $\alpha$-amino $\text{pK}_2 = 9.0$, guanidino $\text{pK}_3 = 12.5$), remaining strongly basic and positively charged across all physiological conditions.

Peptide Formation and Higher-Order Protein Architecture

• Covalent Peptide Bond Formation:

  • A peptide bond is an amide covalent linkage connecting the $\alpha$-carboxyl group of one amino acid to the $\alpha$-amino group of an adjacent amino acid.

  • The reaction proceeds via a condensation/dehydration reaction resulting in the stoichiometric loss of a water molecule ($\text{H}_2\text{O}$).

  • Polypeptide Directionality: Every polypeptide chain has an unreacted amino terminus (N-terminus) on one end and an unreacted carboxyl terminus (C-terminus) on the opposite end, read sequentially from N- to C-terminus.

• The Four Levels of Protein Structural Hierarchy:

  • Primary ($1^\circ$) Structure: The linear sequence of amino acid residues joined by covalent peptide bonds (e.g., $\text{Ala-Leu-Cys-Met}$ or $\text{Ala-Val-Cys-Met}$).

  • Secondary ($2^\circ$) Structure: Localized spatial conformations of the polypeptide backbone, stabilized entirely by hydrogen bonding between the carbonyl oxygen ($-\text{C}=\text{O}$) and amide hydrogen ($-\text{N}-\text{H}$) of peptide linkages:

  • Alpha-Helix ($\alpha$-helix): Right-handed tightly coiled helical configuration with outward-projecting side chains.

  • Beta-Pleated Sheet ($\beta$-pleated sheet): Extended polypeptide strands aligned parallel or antiparallel, stabilized by inter-strand hydrogen bonds.

  • Triple Helix: Three extended helical chains wound around each other, characteristic of tropocollagen.

  • Tertiary ($3^\circ$) Structure: Complete three-dimensional folding of a single polypeptide chain into a compact globular or fibrous architecture, governed by interactions among amino acid R-groups:

  • Hydrophobic Interactions: Burial of non-polar side chains away from aqueous solvent inside the core.

  • Hydrophilic Interactions: Orientation of polar, uncharged residues toward the exterior water shell.

  • Salt Bridges: Electrostatic attractions between ionized acidic ($-\text{COO}^-$) and basic ($-\text{NH}_3^+$) side chains.

  • Hydrogen Bonds: Interactions between polar side-chain functional groups.

  • Disulfide Bonds: Covalent cross-links formed between the thiol groups of two cysteine residues ($-\text{S}-\text{S}-$).

• Quaternary ($4^\circ$) Structure: Spatial organization and non-covalent assembly of two or more distinct tertiary polypeptide subunits into a biologically active oligomeric complex (e.g., adult hemoglobin, which forms an $\alpha_2\beta_2$ tetramer).

  • Molecular Pathology Case Study: Sickle Cell Anemia:

• Genetic Etiology: Caused by a single point mutation in the gene encoding the $\beta$-globin chain of adult hemoglobin ($\text{HbA}$).

• Structural Cascade:

  • Primary Structure Defect: Point mutation substitutes a polar glutamate residue with a non-polar valine residue at position 6 of the $\beta$-globin chain.

  • Quaternary Structure Polymerization: The exposed hydrophobic valine binds to a complementary hydrophobic patch on an adjacent deoxygenated hemoglobin ($\text{HbS}$) tetramer, triggering non-covalent aggregation into long, insoluble polymer fibers.

• Pathophysiological Consequence:

  • Aggregated fibers distort red blood cells into rigid, crescent-shaped ("sickled") erythrocytes.

  • Distorted sickle cells lose mechanical deformability, cannot squeeze through narrow microvascular capillary beds, and cause vaso-occlusion, tissue ischemia, infarction, and intense episodic pain.

Dietary Protein Digestion and Amino Acid Absorption

• Sources of Free Amino Acid Pools:

  • Degradation and absorption of exogenous dietary proteins.

  • De novo biosynthesis of non-essential amino acids primarily within hepatocytes.

  • Endogenous protein turnover: Proteolytic breakdown and continuous re-synthesis of body proteins (recycling old/damaged structural tissues, expired peptide hormones, and metabolic enzymes).

• Gastrointestinal Proteolysis Pipeline:

  • Mouth: Mechanical mastication; salivary fluid contains no active proteolytic enzymes, having no biochemical effect on protein digestion.

  • Stomach:

  • Hydrochloric Acid ($\text{HCl}$): Synthesized by parietal cells; lowers gastric $\text{pH}$, denaturing globular protein structures to uncoil peptide chains and expose internal peptide bonds.

  • Pepsin: Secreted as inactive pepsinogen by chief cells and activated autocatalytically under low $\text{pH}$; acts as an endopeptidase that cleaves exposed internal peptide bonds, yielding large polypeptide fragments.

  • Small Intestine (Lumen):

  • Neutralized by pancreatic bicarbonate ($\text{HCO}_3^-$).

  • Pancreatic Proteases: Endopeptidases (Trypsin, Chymotrypsin) and exopeptidases (Carboxypeptidase, Aminopeptidase) operate cooperatively to hydrolyze polypeptides into oligopeptides, dipeptides, and free amino acids.

• Intestinal Epithelial Absorption:

  • Free amino acids in the intestinal lumen are captured at the brush border apical membrane of enterocytes via specialized $\text{Na}^+$-dependent amino acid co-transporters (secondary active transport).

  • Secondary active transport is driven by the basal-to-apical electrochemical sodium gradient maintained by ATP hydrolysis via the basolateral $\text{Na}^+/\text{K}^+$ ATPase pump ($3\,\text{Na}^+$ pumped out, $2\,\text{K}^+$ pumped in).

  • Accumulated intracellular amino acids exit across the basolateral membrane via facilitative diffusion transporters into the mesenteric capillaries, draining directly into the hepatic portal vein.

Catabolism of Amino Acids: Nitrogen Removal and the Urea Cycle

• Overview of Amino Acid Degradation:

  • Catabolism proceeds through two obligatory phases: removal of the $\alpha$-amino nitrogen group (generating safe excretory products) and subsequent metabolic processing of the remaining carbon skeletons (keto acids).

  • Phase 1: Transamination:

  • Reversible transfer of an $\alpha$-amino group from an amino acid to an $\alpha$-keto acid acceptor (predominantly $\alpha$-ketoglutarate, also termed oxoglutarate), catalyzed by transaminases (aminotransferases).

  • Coenzyme requirement: Pyridoxal phosphate ($\text{PLP}$, derived from vitamin $\text{B}_6$) serves as the prosthetic intermediate electron carrier.

  • Alanine Aminotransferase (ALT):       $\text{Alanine} + \alpha\text{-Ketoglutarate} \rightleftharpoons \text{Pyruvate} + \text{Glutamate}$

  • Aspartate Aminotransferase (AST):       $\text{Aspartate} + \alpha\text{-Ketoglutarate} \rightleftharpoons \text{Oxaloacetate} + \text{Glutamate}$

  • Clinical Diagnostic Relevance: Transaminases normally reside within intracellular hepatocyte cytoplasm and mitochondria. Upon hepatic necrosis, ischemic insult, or inflammatory trauma, large quantities of ALT and AST escape into the plasma, acting as clinical serum biomarkers for early-stage liver damage.

  • Phase 2: Oxidative Deamination:

  • Glutamate generated from peripheral transamination is transported to hepatic mitochondria and deaminated by Glutamate Dehydrogenase ($\text{GDH}$):       $\text{Glutamate} + \text{H}_2\text{O} + \text{NAD(P)}^+ \rightleftharpoons \alpha\text{-Ketoglutarate} + \text{NH}_4^+ + \text{NAD(P)H} + \text{H}^+$

  • Can utilize either $\text{NAD}^+$ or $\text{NADP}^+$ as an electron acceptor.

  • Transdeamination:

  • The physiologically coupled two-step sequence comprising transamination followed by oxidative deamination.

  • Sequentially channels amino groups from multiple peripheral amino acids through glutamate to yield free ammonium ions ($\text{NH}_4^+$) predominantly in the liver and kidney cortex.

• The Hepatic Urea Cycle:

  • Free ammonium ($\text{NH}_4^+$) is neurotoxic; the liver converts ammonia to non-toxic, water-soluble urea via the five-step urea cycle spanning the mitochondrial matrix and cytoplasm.

  • Net Thermodynamic Inputs and Outputs:

  • Inputs: $\text{NH}_3$ (or $\text{NH}_4^+$), $\text{CO}_2$ (as $\text{HCO}_3^-$), Aspartate (source of second urea nitrogen), and $3\,\text{ATP}$ (hydrolyzed across $4$ high-energy phosphate equivalents).

  • Outputs: Urea ($\text{H}_2\text{N}-\text{CO}-\text{NH}_2$), $2\,\text{ADP} + 2\,\text{P}_i$, $\text{AMP} + \text{PP}_i$, and Fumarate.

  • Step-by-Step Biochemical Enzymatic Pathway:

  • Step 1 (Mitochondrial Matrix): Carbamoyl Phosphate Synthetase I ($\text{CPS-I}$) condensates bicarbonate and ammonium, consuming $2\,\text{ATP}$:       $\text{NH}_4^+ + \text{HCO}_3^- + 2\,\text{ATP} \rightarrow \text{Carbamoyl Phosphate} + 2\,\text{ADP} + \text{P}_i$       Absolute Requirement: Obligately activated by N-acetylglutamate ($\text{NAG}$), synthesized from acetyl-CoA and glutamate by N-Acetylglutamate Synthase ($\text{NAGS}$).

  • Step 2 (Mitochondrial Matrix): Ornithine Transcarbamoylase ($\text{OTC}$) transfers the carbamoyl group onto ornithine, producing citrulline:       $\text{Ornithine} + \text{Carbamoyl Phosphate} \rightarrow \text{Citrulline} + \text{P}_i$       Translocation: Citrulline is exported into the cytosol via the ornithine/citrulline antiporter (ORNT1).

  • Step 3 (Cytosol): Argininosuccinate Synthetase ($\text{ASS1}$) condensates citrulline with aspartate, cleaving $1\,\text{ATP}$ to $\text{AMP} + \text{PP}_i$:       $\text{Citrulline} + \text{Aspartate} + \text{ATP} \rightarrow \text{Argininosuccinate} + \text{AMP} + \text{PP}_i$

  • Step 4 (Cytosol): Argininosuccinate Lyase ($\text{ASL}$) cleaves argininosuccinate, liberating fumarate and forming arginine:       $\text{Argininosuccinate} \rightarrow \text{Arginine} + \text{Fumarate}$       Anaplerotic Shunt: Fumarate enters the citric acid cycle or is converted via malate to oxaloacetate for gluconeogenesis.

  • Step 5 (Cytosol): Arginase ($\text{ARG1}$) hydrolytically cleaves arginine, producing urea and regenerating ornithine:       $\text{Arginine} + \text{H}_2\text{O} \rightarrow \text{Urea} + \text{Ornithine}$       Translocation: Regenerated ornithine is imported into the mitochondrial matrix by ORNT1 to sustain cycle turnover.

• Physiological Fate of Urea and Clinical Nephrology:

  • Urea diffuses into systemic circulation and is filtered at the glomerulus for urinary excretion.

  • A physiological portion diffuses across mesenteric vessels into the intestinal lumen, where bacterial flora producing urease hydrolyze it into $\text{CO}_2$ and $\text{NH}_3$.

  • In chronic renal failure, impaired glomerular clearance elevates blood urea nitrogen ($\text{BUN}$), driving excessive flux into the gut and magnifying systemic hyperammonemia.

  • Therapeutic Intervention: Oral administration of neomycin (a non-absorbable aminoglycoside antibiotic) sterilizes urease-producing gut microflora, reducing ammonia generation.

• Inborn Errors of the Urea Cycle:

  • Hyperammonemia Type I: Deficiency in Carbamoyl Phosphate Synthetase I ($\text{CPS-I}$). Autosomal recessive; results in extreme hyperammonemia, lethargy, cerebral edema, mental retardation. Incidence: $1 \text{ in } 100{,}000$.

  • Hyperammonemia Type II: Deficiency in Ornithine Transcarbamoylase ($\text{OTC}$). X-linked recessive inheritance; elevated blood ammonia and accumulation of glutamine in blood, CSF, and urine. Excess mitochondrial carbamoyl phosphate spills into the cytosol, entering pyrimidine synthesis and causing marked orotic aciduria.

  • Hyperornithinemia (HHH Syndrome): Defect in the mitochondrial ornithine transporter-1 ($\text{ORNT1}$) gene; autosomal recessive. Characterized by Hyperornithinemia, Hyperammonemia, and Homocitrullinuria due to impaired ornithine entry into mitochondria, lowering blood urea.

  • Citrullinemia: Deficiency in Argininosuccinate Synthetase ($\text{ASS1}$). Autosomal recessive; marked hyperammonemia alongside dramatic citrulline accumulation ($1\text{--}2\,\text{g/day}$ excreted in urine).

  • Argininosuccinic Aciduria: Deficiency in Argininosuccinate Lyase ($\text{ASL}$). Argininosuccinate accumulates in plasma and urine; manifests with friable, tufted brittle hair (trichorrhexis nodosa). Incidence: $3 \text{ in } 200{,}000$.

  • Hyperargininemia: Deficiency in Arginase ($\text{ARG1}$). Elevated arginine in blood and CSF. Instead of arginine, urinary wasting of cysteine and lysine occurs. Incidence: $1 \text{ in } 100{,}000$.

Carbon Skeleton Degradation and Inborn Errors of Metabolism

• Metabolic Fate of Amino Acid Carbon Skeletons:

  • Once deaminated, carbon skeletons are processed into metabolic intermediates classified by their ultimate metabolic destinies:

  • Glucogenic Amino Acids: Degrade into pyruvate or intermediates of the citric acid cycle ($\alpha$-ketoglutarate, succinyl-CoA, fumarate, oxaloacetate), capable of entering gluconeogenesis to synthesize glucose.

  • Ketogenic Amino Acids: Degrade directly into acetyl-CoA or acetoacetyl-CoA, serving as precursors for fatty acid synthesis and ketogenesis. Leucine and Lysine are purely ketogenic.

  • Both Glucogenic and Ketogenic: Isoleucine, Phenylalanine, Tryptophan, and Tyrosine.

• Specific Degradative Pathways:

  • Pyruvate Convergent Route:

  • Threonine is oxidized by threonine dehydrogenase ($\text{TDH}$) using $\text{NAD}^+$ to form 2-amino-3-ketobutyrate, which CoA cleaves into acetyl-CoA and glycine.

  • Glycine is converted to serine via a $\text{PLP}$-dependent enzyme or cleaved by the glycine cleavage system into $\text{CO}_2$, $\text{NH}_4^+$, and $\text{NADH}$.

  • Serine undergoes dehydration and deamination via serine dehydratase ($\text{PLP}$-dependent) to yield pyruvate and $\text{NH}_4^+$.

  • Alanine transaminates directly to pyruvate via ALT ($\text{PLP}$-dependent).

  • Cysteine undergoes degradation in two enzymatic steps to yield pyruvate.

  • Tryptophan catabolism proceeds through a multi-step pathway to generate alanine, which subsequently yields pyruvate.

• Catabolism of Phenylalanine and Tyrosine:

  • Phenylalanine is converted to Tyrosine via Phenylalanine Hydroxylase ($\text{PAH}$), requiring molecular oxygen ($\text{O}_2$) and tetrahydrobiopterin ($\text{BH}_4$) as an obligate electron donor cofactor:     $\text{Phenylalanine} + \text{BH}_4 + \text{O}_2 \rightarrow \text{Tyrosine} + \text{BH}_2 + \text{H}_2\text{O}$

  • Tyrosine undergoes transamination by tyrosine aminotransferase to yield $\text{p}$-hydroxyphenylpyruvate.

  • Oxidation by $\text{p}$-hydroxyphenylpyruvate dioxygenase (with $\text{O}_2$ and decarboxylation of $\text{CO}_2$) forms homogentisate.

  • Homogentisate 1,2-dioxygenase oxidatively cleaves the aromatic ring of homogentisate using $\text{O}_2$ to yield maleylacetoacetate.

  • Maleylacetoacetate isomerase rearranges the compound into fumarylacetoacetate.

  • Fumarylacetoacetate hydrolase cleaves the intermediate with water into Fumarate (glucogenic) and Acetoacetate (ketogenic).

  • Acetoacetate is converted to acetoacetyl-CoA via succinyl-CoA transferase.

• Pathology of Inborn Errors of Amino Acid Metabolism:

  • Phenylketonuria (PKU):

  • Enzyme Deficiency: Phenylalanine hydroxylase ($\text{PAH}$) defect.

  • Pathophysiological Accumulation: Severe systemic elevation of phenylalanine. Secondary transamination shunts phenylalanine into phenylpyruvate, phenyllactate, and phenylacetate.

  • Clinical Manifestations: Severe progressive intellectual disability, microcephaly, epileptic seizures, and a characteristic musty/mousy odor to urine and perspiration.

  • Therapeutic Management: Strict dietary restriction of phenylalanine and supplementation with tyrosine. Artificial sweetener warning: Aspartame (L-aspartyl-L-phenylalanine methyl ester) must be excluded from the diet.

  • Maple Syrup Urine Disease (MSUD):

  • Enzyme Deficiency: Branched-chain $\alpha$-ketoacid dehydrogenase complex ($\text{BCKDC}$), a mitochondrial multienzyme complex.

  • Substrates Affected: Branched-chain amino acids (BCAAs): Leucine, Isoleucine, Valine.

  • Pathophysiological Accumulation: Branched-chain amino acids and their toxic $\alpha$-ketoacids (e.g., $\alpha$-ketoisocaproate from leucine, $\alpha$-keto-$\beta$-methylvalerate from isoleucine, $\alpha$-ketoisovalerate from valine).

  • Clinical Manifestations: Sweet, burnt-sugar or maple syrup odor of the urine, poor feeding, severe ketoacidosis, lethargy, encephalopathy, coma, and neonatal mortality if untreated.

  • Therapeutic Management: Lifelong restriction of dietary leucine, isoleucine, and valine.

  • Alkaptonuria:

  • Enzyme Deficiency: Homogentisate oxidase (homogentisate 1,2-dioxygenase).

  • Substrate Affected: Homogentisic acid (intermediate in tyrosine catabolism).

  • Clinical Manifestations: Urine turns dark black upon standing/oxidation; ochronosis (deposition of black-brown pigment in connective tissues, sclerae, and auricles); severe debilitating degenerative arthritis in later adult life.

  • Therapeutic Management: Dietary restriction of phenylalanine and tyrosine; symptomatic support and high-dose ascorbic acid (vitamin C) to limit pigment oxidation.

  • Homocystinuria:

  • Enzyme Deficiency: Cystathionine $\beta$-synthase ($\text{CBS}$), requiring pyridoxal phosphate ($\text{PLP}$).

  • Substrate Involved: Homocysteine (from methionine demethylation cycle):       $\text{Homocysteine} + \text{Serine} \rightarrow \text{Cystathionine}$

  • Clinical Manifestations: Downward/inward ectopia lentis (dislocation of ocular lenses), osteoporosis, marfanoid habitus, intellectual disability, and early-onset life-threatening thromboembolism in systemic arteries and veins.

  • Therapeutic Management: High-dose vitamin $\text{B}_6$ (pyridoxine), low-methionine diet supplemented with L-cysteine, and antiplatelet therapy to mitigate thrombotic complications.

  • Tyrosinemia Variants:

  • Tyrosinemia Type I: Fumarylacetoacetate hydrolase deficiency; causes liver failure, renal tubular dysfunction (Fanconi syndrome), and peripheral neuropathy.

  • Tyrosinemia Type II: Tyrosine aminotransferase deficiency; causes ocular keratitis, hyperkeratotic skin lesions on palms/soles, and intellectual delay.

  • Tyrosinemia Type III: $\text{p}$-Hydroxyphenylpyruvate dioxygenase deficiency; benign or accompanied by mild cognitive deficits.

Lipid Classification, Chemical Structures, and Properties

• Physicochemical Properties and Bloor's Classification:

  • Lipids comprise a structurally diverse class of hydrophobic or amphipathic organic compounds that are insoluble in water but freely soluble in non-polar organic solvents (ether, chloroform, benzene, acetone).

  • Typical human adult dietary intake averages approximately $81\,\text{g}$ of lipid daily, of which approximately $90\%$ consists of triacylglycerol ($\text{TAG}$).

  • Bloor's Systematic Classification:

  • Simple Lipids: Esters of fatty acids with various alcohols.

    • Fats and Oils: Neutral esters of fatty acids with the trihydric alcohol glycerol (triacylglycerols / triglycerides).

    • Waxes: Esters of long-chain fatty acids with high-molecular-weight monohydric aliphatic alcohols.

  • Compound (Complex) Lipids: Esters of fatty acids containing non-lipid chemical groups attached to the alcohol-fatty acid core.

    • Phospholipids: Possess a substituted phosphate ester, fatty acid chains, and a nitrogenous base.

    • Glycerophospholipids: Contain a glycerol backbone (e.g., phosphatidylcholine, phosphatidylethanolamine).

    • Sphingophospholipids: Contain an amino alcohol sphingosine backbone (e.g., sphingomyelin, a component of the myelin sheath).

    • Glycolipids (Glycosphingolipids): Contain carbohydrate moieties linked to a ceramide core without a phosphate group.

    • Cerebrosides: Simple glycolipids with a single monosaccharide unit (glucose or galactose) attached to ceramide.

    • Gangliosides: Complex glycolipids with branched oligosaccharide chains terminating in one or more acidic sialic acid ($\text{N}$-acetylneuraminic acid) residues.

    • Proteolipids: Protein-lipid complexes possessing high lipid content.

  • Derived Lipids: Hydrolytic derivatives and structural components originating from simple and complex lipids, including free fatty acids, sterols (cholesterol), long-chain alcohols, eicosanoids, and isoprenoids.

• Structural Features of Fatty Acids:

  • Consist of an amphipathic structure containing a hydrophilic polar terminal carboxyl group ($-\text{COOH}$) linked to a non-polar hydrophobic hydrocarbon chain.

  • Classification Based on Chain Length:

  • Short-Chain Fatty Acids (SCFAs): $\le 5$ carbon atoms (e.g., butyric acid, produced via anaerobic bacterial fermentation of dietary fiber in the colon).

  • Medium-Chain Fatty Acids (MCFAs): $6 \text{ to } 12$ carbon atoms (e.g., caprylic acid, capric acid; found in coconut oil and bovine milk fat).

  • Long-Chain Fatty Acids (LCFAs): $13 \text{ to } 21$ carbon atoms (e.g., palmitic acid [$16:0$], oleic acid [$18:1$]; dominant dietary forms).

  • Very Long-Chain Fatty Acids (VLCFAs): $\ge 22$ carbon atoms (e.g., cerotic acid [$26:0$], montanic acid [$28:0$]).

  • Degree of Saturation:

  • Saturated Fatty Acids: Carbon chains containing no double bonds ($\text{C}-\text{C}$ single bonds exclusively), packed tightly into rigid conformations. Examples: Myristic acid ($14:0$), Palmitic acid ($16:0$), Stearic acid ($18:0$).

  • Monounsaturated Fatty Acids (MUFAs): Hydrocarbon chains containing exactly one double bond. Examples: Oleic acid ($18:1\,\Delta^9$, cis configuration; abundant in olive oil), Palmitoleic acid ($16:1\,\Delta^9$).

  • Polyunsaturated Fatty Acids (PUFAs): Possess two or more double bonds along the carbon chain.

    • Omega-6 ($\text{n}-6$) Family: First double bond located at the sixth carbon from the methyl (omega) end. Examples: Linoleic acid ($18:2\,\Delta^{9,12}$), Arachidonic acid ($20:4\,\Delta^{5,8,11,14}$).

    • Omega-3 ($\text{n}-3$) Family: First double bond located at the third carbon from the methyl end. Examples: Alpha-linolenic acid ($\text{ALA}$, $18:3\,\Delta^{9,12,15}$), Eicosapentaenoic acid ($\text{EPA}$, $20:5\,\Delta^{5,8,11,14,17}$), Docosahexaenoic acid ($\text{DHA}$, $22:6\,\Delta^{4,7,10,13,16,19}$).

• Structure and Conformation of Cholesterol:

  • Derived steroid lipid featuring the planar tetracyclic cyclopentanoperhydrophenanthrene ring nucleus (composed of four fused rings labeled A, B, C, and D with $17$ numbered skeletal carbon positions).

  • Features an aliphatic branched hydrocarbon tail attached at carbon-17, methyl groups at positions 10 and 13, and a polar hydroxyl group ($-\text{OH}$) located at carbon-3.

  • Functions as a dynamic regulator of eukaryotic membrane fluidity and the obligate biological precursor for bile salts, steroid hormones (cortisol, aldosterone, testosterone, estradiol), and vitamin D.

Digestion, Absorption, and Mobilization of Lipids

• Intraluminal Digestion of Dietary Lipids:

  • Gastric Processing: Mechanical churning in the stomach creates an emulsion. Lingual lipase and gastric lipase (acid-stable lipases, optimal at $\text{pH } 4\text{--}6$) initiate lipolysis, cleaving short- and medium-chain fatty acids at the sn-3 position of triacylglycerols.

  • Duodenal Emulsification: Mechanical peristalsis combined with the biological amphipathic detergent properties of bile salts (glycocholate, taurocholate) emulsifies large lipid globules into microscopic mixed micelles, increasing surface area for enzymatic attack.

  • Pancreatic Enzymatic Degradation:

  • Pancreatic Lipase and Colipase: Hydrolyzes the primary ester linkages at positions sn-1 and sn-3 of triacylglycerol, yielding free fatty acids and 2-monoacylglycerol (2-MAG).

  • Pancreatic Cholesteryl Ester Hydrolase (Cholesterol Esterase): Hydrolyzes dietary cholesteryl esters into unesterified cholesterol and free fatty acids.

  • Phospholipase $\text{A}_2$: Cleaves the fatty acyl moiety at carbon-2 of phospholipids, yielding a lysophospholipid and a free fatty acid.

  • Micellar Absorption: Mixed micelles diffuse through the unstirred water layer of the intestinal brush border; free fatty acids, 2-MAG, and cholesterol are absorbed passively across enterocyte membranes, where they are re-esterified into triacylglycerols and packaged into chylomicrons for exocytosis into the lacteals.

• Mobilization of Adipose Lipids (Lipolysis):

  • Hormonal Triggering: In fasting states, during intense muscular exertion, or in acute hypoglycemia, counter-regulatory catabolic hormones (glucagon, epinephrine, norepinephrine, cortisol) bind to adipocyte transmembrane $\text{G}_s$-protein-coupled receptors.

  • Signaling Cascade:

  • Adenylyl cyclase is activated, converting $\text{ATP}$ into cyclic AMP ($\text{cAMP}$).

  • Elevated intracellular $\text{cAMP}$ activates Protein Kinase A ($\text{PKA}$).

  • Active PKA phosphorylates two regulatory target proteins: Perilipin and Hormone-Sensitive Lipase ($\text{HSL}$).

  • Enzymatic Cascade:

  • Phosphorylated perilipin shifts its conformation on the lipid droplet surface, allowing phosphorylated HSL access to the triacylglycerol core.

  • Triacylglycerol is cleaved into diacylglycerol, monoacylglycerol, and ultimately three free fatty acid molecules plus one glycerol.

  • Circulatory Transport:

  • Free Fatty Acids: Insoluble in aqueous plasma; they exit adipocytes and bind non-covalently to plasma albumin for vascular transit to peripheral tissues (skeletal muscle, myocardium, renal cortex).

  • Glycerol: Highly water-soluble; dissolved directly in plasma and transported to the liver, where glycerol kinase converts it into glycerol-3-phosphate for gluconeogenesis or glycolysis.

Mitochondrial Transport and Beta-Oxidation of Fatty Acids

• Cytosolic Activation of Free Fatty Acids:

  • Free fatty acids entering the cytoplasm must be activated to prevent back-diffusion and prepare for oxidation.

  • Fatty Acyl-CoA Synthetase (Thiokinase) on the outer mitochondrial membrane catalyzes the reaction:     $\text{Fatty Acid} + \text{ATP} + \text{CoA-SH} \xrightarrow{\text{Mg}^{2+}} \text{Fatty Acyl-CoA} + \text{AMP} + \text{PP}_i$

  • Pyrophosphatase hydrolyzes pyrophosphate ($\text{PP}_i \rightarrow 2\,\text{P}_i$), driving the reaction forward and consuming $2$ high-energy phosphate equivalents.

• The Carnitine Shuttle System:

  • Long-chain fatty acyl-CoA cannot cross the impermeable inner mitochondrial membrane and relies on the carnitine transport shuttle.

  • Step 1 (Outer Membrane): Carnitine Palmitoyltransferase I ($\text{CPT-I}$) transfers the fatty acyl moiety from coenzyme A to carnitine, producing fatty acyl-carnitine and releasing free cytosolic $\text{CoA-SH}$.

  • Step 2 (Inner Membrane Translocation): Carnitine-Acylcarnitine Translocase ($\text{CACT}$) antiports fatty acyl-carnitine across the inner mitochondrial membrane into the matrix while exporting free carnitine into the intermembrane space.

  • Step 3 (Mitochondrial Matrix): Carnitine Palmitoyltransferase II ($\text{CPT-II}$) transfers the fatty acyl group from carnitine back onto a matrix $\text{CoA-SH}$, regenerating fatty acyl-CoA and freeing carnitine.

• The Four Core Cyclic Steps of $\beta$-Oxidation:

  • Each cycle of mitochondrial $\beta$-oxidation removes a two-carbon fragment as acetyl-CoA via four sequential reactions:

  • Step 1: First Oxidation (Dehydrogenation):

  • Enzyme: Acyl-CoA Dehydrogenase.

  • Removes hydrogens from the $\alpha$ ($\text{C}_2$) and $\beta$ ($\text{C}_3$) carbons, creating a trans double bond and forming $\text{trans-}\Delta^2\text{-enoyl-CoA}$.

  • Coenzyme $\text{FAD}$ is reduced to $\text{FADH}_2$, yielding $\approx 1.5\,\text{ATP}$ in the electron transport chain.

  • Step 2: Hydration:

  • Enzyme: Enoyl-CoA Hydratase.

  • Adds a water molecule across the trans double bond, introducing a hydroxyl group onto the $\beta$-carbon to form L-$\beta$-hydroxyacyl-CoA.

  • Step 3: Second Oxidation (Dehydrogenation):

  • Enzyme: $\beta$-Hydroxyacyl-CoA Dehydrogenase.

  • Oxidizes the hydroxyl group on the $\beta$-carbon into a keto group, forming $\beta$-ketoacyl-CoA.

  • Coenzyme $\text{NAD}^+$ is reduced to $\text{NADH} + \text{H}^+$, yielding $\approx 2.5\,\text{ATP}$ via oxidative phosphorylation.

  • Step 4: Thiolytic Cleavage (Thiolysis):

  • Enzyme: $\beta$-Ketothiolase (Acyl-CoA Acetyltransferase).

  • Directs nucleophilic attack by a new coenzyme A ($\text{CoA-SH}$) molecule across the bond between the $\alpha$ and $\beta$ carbons.

  • Releases a shortened fatty acyl-CoA ($n-2$ carbons) and an acetyl-CoA molecule ($2$ carbons) that enters the citric acid cycle.

• Stoichiometric Energetics of Palmitic Acid Oxidation ($16:0$):

  • Cleavage of palmitic acid ($16$ carbons) requires $7$ successive cycles of $\beta$-oxidation.

  • Metabolic Yield:

  • $8\,\text{Acetyl-CoA}$

  • $7\,\text{NADH}$

  • $7\,\text{FADH}_2$

  • ATP Yield Calculations:

  • From $7\,\text{NADH} \times 2.5\,\text{ATP} = 17.5\,\text{ATP}$

  • From $7\,\text{FADH}_2 \times 1.5\,\text{ATP} = 10.5\,\text{ATP}$

  • From $8\,\text{Acetyl-CoA} \times 10\,\text{ATP}$ (via TCA cycle) $= 80.0\,\text{ATP}$

  • Gross Total Generated: $108.0\,\text{ATP}$

  • Priming/Activation Deduction (Thiokinase reaction): $-2.0\,\text{ATP}$

  • Net Overall Energy Yield: $106.0\,\text{ATP}$

• Oxidation of Odd-Chain Fatty Acids:

  • Undergoes conventional rounds of $\beta$-oxidation until a three-carbon terminal fragment, propionyl-CoA, remains.

  • Three-Step Anaplerotic Pathway:

  • Step 1: Propionyl-CoA Carboxylase incorporates $\text{HCO}_3^-$ consuming $1\,\text{ATP}$ (requiring biotin as an active prosthetic carrier) to synthesize D-methylmalonyl-CoA.

  • Step 2: Methylmalonyl-CoA Epimerase converts D-methylmalonyl-CoA into its L-enantiomer, L-methylmalonyl-CoA.

  • Step 3: Methylmalonyl-CoA Mutase catalyzes an intramolecular carbon skeleton rearrangement, requiring Coenzyme $\text{B}_{12}$ (deoxyadenosylcobalamin), to generate Succinyl-CoA.

  • Succinyl-CoA enters the citric acid cycle for terminal oxidation or gluconeogenic synthesis.

Biosynthesis of Triacylglycerols and De Novo Fatty Acid Synthesis

• Biosynthesis of Triacylglycerols (TAG):

  • Primary anabolic pathway for long-term energy storage occurring mainly in hepatocytes and adipocytes.

  • Substrate Precursors: Glycerol-3-phosphate (derived from dihydroxyacetone phosphate via glycerol-3-phosphate dehydrogenase in adipose/liver, or from glycerol via glycerol kinase in liver only) and fatty acyl-CoAs.

  • Sequential Acylation Pipeline:

  • Acylation 1: Glycerol-3-Phosphate Acyltransferase ($\text{GPAT}$) transfers a fatty acyl chain to the sn-1 position of glycerol-3-phosphate, producing lysophosphatidic acid.

  • Acylation 2: 1-Acylglycerol-3-Phosphate Acyltransferase ($\text{AGPAT}$) attaches a second fatty acyl chain at the sn-2 position, forming phosphatidic acid (1,2-diacylglycerol phosphate).

  • Dephosphorylation: Phosphatidic Acid Phosphatase ($\text{PAP}$, Lipin-1) removes the phosphate group from phosphatidic acid, producing 1,2-diacylglycerol ($\text{DAG}$).

  • Acylation 3: Diacylglycerol Acyltransferase ($\text{DGAT}$) attaches a third fatty acyl chain to the remaining sn-3 position of DAG, producing mature triacylglycerol ($\text{TAG}$).

• De Novo Biosynthesis of Fatty Acids (Lynen's Spiral):

  • Elucidated by Nobel laureate Feodor Lynen (1964); operates as an anabolic pathway in the cytosol of liver, lactating mammary glands, adipose tissue, renal cortex, and brain.

  • Synthesizes saturated palmitic acid ($16:0$) from acetyl-CoA precursors.

• Mitochondrial-to-Cytosolic Transport of Acetyl Units:

  • Acetyl-CoA is generated within the mitochondrial matrix and cannot cross the inner mitochondrial membrane.

  • The Citrate-Malate Shuttle:

  • Mitochondrial Citrate Synthase condenses acetyl-CoA with oxaloacetate to form citrate.

  • Citrate crosses into the cytosol via the tricarboxylic acid transporter.

  • Cytosolic ATP-Citrate Lyase cleaves citrate, consuming $1\,\text{ATP}$ to regenerate cytosolic acetyl-CoA and oxaloacetate:       $\text{Citrate} + \text{CoA} + \text{ATP} \rightarrow \text{Acetyl-CoA} + \text{Oxaloacetate} + \text{ADP} + \text{P}_i$

  • Cytosolic Malate Dehydrogenase reduces oxaloacetate to malate using $\text{NADH}$.

  • Malic Enzyme oxidatively decarboxylates malate to pyruvate, generating cytosolic $\text{NADPH}$ for fatty acid synthesis:       $\text{Malate} + \text{NADP}^+ \rightarrow \text{Pyruvate} + \text{CO}_2 + \text{NADPH}$

  • Pyruvate crosses back into the mitochondria via the pyruvate translocase.

• The Fatty Acid Synthase (FAS) Multienzyme Complex:

  • Homodimeric structural complex encoded by a single gene, containing two identical subunits aligned head-to-tail with seven catalytic activities and an Acyl Carrier Protein ($\text{ACP}$) domain carrying a 4'-phosphopantetheine prosthetic arm.

  • Step-by-Step Elongation Cycle:

  • Step 1: Carboxylation (Rate-Limiting Reaction):

    • Acetyl-CoA Carboxylase ($\text{ACC}$), a biotin-dependent enzyme, carboxylates acetyl-CoA to malonyl-CoA:         $\text{Acetyl-CoA} + \text{CO}_2 + \text{ATP} \xrightarrow{\text{Biotin}} \text{Malonyl-CoA} + \text{ADP} + \text{P}_i$

  • Step 2A: Acetyl Transacylase ($\text{AT}$) loads an initial acetyl priming group ($2\,\text{C}$) onto the cysteinyl sulfhydryl group ($-\text{SH}$) of the Condensing Enzyme ($\text{CE} / \beta\text{-ketoacyl synthase}$.

  • Step 2B: Malonyl Transacylase ($\text{MT}$) loads a malonyl group ($3\,\text{C}$) onto the phosphopantetheine sulfhydryl group ($-\text{SH}$) of the Acyl Carrier Protein ($\text{ACP}$).

  • Step 3: Condensation:

    • Condensing Enzyme / $\beta$-Ketoacyl Synthase drives decarboxylative condensation of the acetyl group with the malonyl-ACP, releasing $\text{CO}_2$ to form acetoacetyl-ACP ($\beta$-ketoacyl-ACP, $4\,\text{C}$).

  • Step 4: First Reduction:

    • $\beta$-Ketoacyl Reductase ($\text{KR}$) reduces the $\beta$-keto group using $\text{NADPH} + \text{H}^+$, yielding $\beta$-hydroxybutyryl-ACP.

  • Step 5: Dehydration:

    • $\beta$-Hydroxyacyl Dehydratase ($\text{DH}$) removes a water molecule, introducing a trans double bond to form enoyl-ACP (crotonyl-ACP).

  • Step 6: Second Reduction:

    • Enoyl Reductase ($\text{ER}$) reduces the double bond using a second $\text{NADPH} + \text{H}^+$, forming butyryl-ACP ($4\,\text{C}$ fully saturated).

  • Repetition and Cleavage: Steps 3 through 6 repeat for $7$ total rounds until a $16$-carbon palmitoyl-ACP is formed. Thioesterase ($\text{TE}$, Step 7) hydrolyzes palmitate from the complex, releasing free palmitic acid.

Regulation of Lipid Metabolism and Associated Disorders

• Coordinated Control of Fatty Acid Synthesis and Oxidation:

  • Allosteric Control of Acetyl-CoA Carboxylase (ACC):

  • Activation: Citrate acts as an allosteric activator, inducing polymer assembly of inactive ACC protomers into active filaments.

  • Inhibition: Palmitoyl-CoA (the pathway end product) causes depolymerization and feedback inhibition.

  • Covalent Phosphorylation of ACC:

  • Inactivation: AMP-Activated Protein Kinase ($\text{AMPK}$) phosphorylates and inactivates ACC when cellular energy is depleted (elevated $\text{AMP}$:$\text{ATP}$ ratio). Glucagon and epinephrine stimulate phosphorylation via PKA, turning off lipogenesis during fasting.

  • Activation: Protein Phosphatase 1 ($\text{PP1}$) dephosphorylates and activates ACC in response to insulin signaling during the fed state.

  • Reciprocal Inhibition of $\beta$-Oxidation:

  • Malonyl-CoA, the intermediate produced by active ACC, potently inhibits Carnitine Palmitoyltransferase I ($\text{CPT-I}$).

  • This prevents newly synthesized fatty acids from entering mitochondria, avoiding a futile cycle of concurrent lipogenesis and $\beta$-oxidation.

• Metabolic Disorders of Lipid Handling:

  • Systemic Carnitine Deficiency:

  • Caused by defects in carnitine biosynthesis or impaired membrane transport.

  • Impairs long-chain fatty acid entry into mitochondria, blocking $\beta$-oxidation.

  • Manifests as hypoketotic hypoglycemia, systemic muscle weakness, lipid deposition in myocytes, and cardiomyopathy during fasting.

  • Glycerol Kinase Deficiency:

  • X-linked recessive disorder impairing the conversion of glycerol to glycerol-3-phosphate in hepatocytes.

  • Leads to pseudo-hypertriglyceridemia, glyceroluria, metabolic acidosis, and episodic hypoglycemia.

  • HMG-CoA Lyase Deficiency:

  • Impairs the final enzymatic step of ketone body synthesis and leucine catabolism.

  • Causes severe hypoketotic hypoglycemia, metabolic acidosis, hyperammonemia, and hepatic steatosis under fasting stress.

  • Obesity and Metabolic Syndrome:

  • Sustained positive caloric balance drives adipose tissue hypertrophy and macrophage infiltration.

  • Saturated adipose capacity leads to ectopic lipid accumulation (lipotoxicity) in hepatocytes and skeletal myocytes.

  • Diacylglycerol and ceramide accumulation triggers cellular stress, insulin receptor signaling blunting, and non-alcoholic fatty liver disease ($\text{NAFLD}$).

  • Hyperlipidemia in Diabetes Mellitus:

  • In absolute or relative insulin deficiency, uninhibited adipocyte lipolysis mediated by HSL continuously dumps free fatty acids into systemic circulation.

  • Excessive hepatic influx of free fatty acids drives rapid triacylglycerol synthesis and secretion of Very Low-Density Lipoproteins ($\text{VLDL}$).

  • Concomitant reduction in insulin-dependent Lipoprotein Lipase ($\text{LPL}$) activity on capillary endothelia impairs clearance of chylomicrons and VLDL, causing severe mixed dyslipidemia.